Ascendis Pharma (ASND) Reiterated at Overweight by Cantor Fitzgerald After Model Update
Tweet Send to a Friend
Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating and $300.00 price target on Ascendis Pharma (NASDAQ: ASND).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
